Biogen Idec Inc.and Bayer AG would have to cut the price of their multiple sclerosis drugs by at least two-thirds in the U.S. to make them cost effective at boosting quality of life, a study found.
As context, it’s worth noting that the research did not address whether disease-modifying drugs affected the likelihood, timing or severity of MS progression, the most disabling aspect of MS; because such progression typically becomes noticeable many years after disease onset. The study was based on up to four years of data from observational studies, so it did not capture these outcome measures.
Loobie wrote:The drugs simply don't work.
Users browsing this forum: Kronk